GLP-1 receptor agonists can cause significant lean mass loss alongside weight reduction, but preclinical evidence suggests they may also protect muscle at the cellular level, with diet, exercise, and myostatin blockers as potential countermeasures.
Muscle loss paradoxClinical lean mass loss occurs with GLP-1 drugs, yet preclinical data shows direct muscle-protective effects—suggesting countermeasures could resolve the concern
What the researchers found
Clinical studies show GLP-1RAs and dual GLP-1/GIP agonists can cause significant lean mass loss and sarcopenia risk, but preclinical evidence paradoxically shows these agents may attenuate skeletal muscle atrophy, improve muscle function, and enhance mitochondrial health at the cellular level.
Why it matters
With millions now taking GLP-1 drugs for weight loss, understanding whether muscle loss is an inevitable side effect or a manageable concern is critical. Sarcopenia—loss of muscle mass and function—can lead to frailty, falls, and metabolic decline, especially in older adults.
The numbers in context
GLP-1 RAs and dual GLP-1/GIP RAs linked to significant lean mass reductions in clinical studies. Preclinical data show improved mitochondrial health and attenuated muscle atrophy. GDF8 and activin A blockade proposed as countermeasures.
How the study worked
Brief narrative review synthesizing clinical and preclinical evidence on the relationship between GLP-1-based therapies and muscle health.
Who was studied
Patients with type 2 diabetes or obesity on GLP-1-based therapies
What this study cannot tell us
Narrative review with limited systematic methodology. Preclinical muscle-protective findings may not translate to clinical settings. Clinical data on lean mass preservation strategies during GLP-1 therapy are limited. The review does not distinguish between lean mass types (muscle vs. organ tissue).
How to read the evidence
Brief narrative review mixing clinical observations of lean mass loss with preclinical evidence of muscle protection. Evidence is emerging and somewhat contradictory, requiring further clinical trials to resolve.
When this study was published
Published in 2025; addresses one of the most pressing safety questions about the rapidly expanding use of GLP-1 drugs.
The bigger picture
The muscle loss concern is one of the most important safety questions surrounding the GLP-1 drug revolution. This review suggests the answer is nuanced: whole-body lean mass loss occurs during weight reduction, but direct muscle-protective effects may exist at the cellular level. Combining GLP-1 drugs with muscle-preserving interventions could be key to safe long-term use.
Questions still open
- Can resistance exercise fully offset the lean mass loss caused by GLP-1 agonists?
- Will myostatin/activin A blockers combined with GLP-1 drugs preserve muscle while maintaining weight loss benefits?
- Does the type of lean mass lost (muscle vs. other lean tissue) differ between GLP-1 drugs?
Common questions
Do GLP-1 weight loss drugs cause muscle loss?
How can you prevent muscle loss while taking GLP-1 drugs?
Read the original research
GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review.
Diabetes research and clinical practice, 229, 112924
Citation
Pantazopoulos, Dimitrios; Gouveri, Evanthia; Papazoglou, Dimitrios; Papanas, Nikolaos. (2025). GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review.. Diabetes research and clinical practice, 229, 112924. https://doi.org/10.1016/j.diabres.2025.112924